TapewireFind a company

person · Reporting owner

Thorp Clay

Disclosed activity across 4 companies

Tapewire entity
82876
SEC CIK
0001592380

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Clearside Biomedical, Inc.CLSD · Entity 82875DirectorFebruary 24, 2025February 24, 2025
G1 Therapeutics, Inc.GTHX · Entity 8741310% ownerMay 30, 2018June 01, 2018
PhaseBio Pharmaceuticals IncPHAS · Entity 113305DirectorMay 19, 2023May 19, 2023
Vigil Neuroscience, Inc.VIGL · Entity 11675DirectorMay 16, 2022May 17, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Clearside Biomedical, Inc.

Report date February 24, 2025 · Filed February 24, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect176,141 Reported balance After 2025-02-24 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2025-02-24 · Purchase · Acquired 15,000 · Balance 176,141

F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.9321 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: Includes an aggregate of 120,619 shares received as a pro rata distribution from Hatteras Venture Advisors III, LLC, Hatteras Venture Advisors IV SBIC, LLC, Hatteras Venture Advisors IV, LLC and Hatteras NC Fund, LP (the "Hatteras Entities"). In prior reports, the reporting person reported indirect beneficial ownership of 3,545,040 shares of the Issuer's common stock held by the Hatteras Entities.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.9321 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: Includes an aggregate of 120,619 shares received as a pro rata distribution from Hatteras Venture Advisors III, LLC, Hatteras Venture Advisors IV SBIC, LLC, Hatteras Venture Advisors IV, LLC and Hatteras NC Fund, LP (the "Hatteras Entities"). In prior reports, the reporting person reported indirect beneficial ownership of 3,545,040 shares of the Issuer's common stock held by the Hatteras Entities.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnotes3,279,421 Reported balance After 2018-05-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2018-05-30 · Sale · Disposed 758,290 · Balance 3,279,421

F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F2: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F3: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnotes3,237,711 Reported balance After 2018-05-30 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2018-05-30 · Sale · Disposed 41,710 · Balance 3,237,711

F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F4: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC.

F5: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV.

Filing footnotes · ownership attribution and instrument terms

F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F2: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F3: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F4: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC.

F5: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV.

PhaseBio Pharmaceuticals Inc

Report date May 19, 2023 · Filed May 19, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect36,693 Reported balance After 2023-05-19 transaction · row 1
1 source row

Row 1 · 2023-05-19 · Exercise / conversion · Acquired 3,750 · Balance 36,693

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2023-05-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2023-05-19 · Exercise / conversion · Acquired 3,750 · Balance 0

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.

F4: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date.

Common StockSEC Table I · non-derivativeIndirectSee footnote3,545,040 Reported balance Holding disclosure · report date 2023-05-19 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 3,545,040

F2: The Reporting Person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP ("HVP IV") and Hatteras NC Fund, LP ("Hatteras NC"). HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.

F3: The Reporting Person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.

F2: The Reporting Person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP ("HVP IV") and Hatteras NC Fund, LP ("Hatteras NC"). HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.

F3: The Reporting Person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F4: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date.

Vigil Neuroscience, Inc.

Report date May 16, 2022 · Filed May 17, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Hatteras Venture Partners VI, L.P.1,556,030 Last balance in matching sequence After 2022-05-17 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2022-05-16 · Purchase · Acquired 21,802 · Balance 1,541,137

F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.50 to $2.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.

F2: These shares are held directly by Hatteras Venture Partners VI, L.P. ("Hatteras VI"). Hatteras Venture Advisors VI, LLC ("HVA VI") is the general partner of Hatteras VI. The Reporting Person is a managing member of HVA VI and disclaims beneficial ownership of the shares held by Hatteras VI except to the extent of his pecuniary interest therein, if any.

Row 2 · 2022-05-17 · Purchase · Acquired 14,893 · Balance 1,556,030

F3: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.76 to $3.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.

F2: These shares are held directly by Hatteras Venture Partners VI, L.P. ("Hatteras VI"). Hatteras Venture Advisors VI, LLC ("HVA VI") is the general partner of Hatteras VI. The Reporting Person is a managing member of HVA VI and disclaims beneficial ownership of the shares held by Hatteras VI except to the extent of his pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeDirect3,000 Reported balance Holding disclosure · report date 2022-05-16 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 3,000

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.50 to $2.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.

F2: These shares are held directly by Hatteras Venture Partners VI, L.P. ("Hatteras VI"). Hatteras Venture Advisors VI, LLC ("HVA VI") is the general partner of Hatteras VI. The Reporting Person is a managing member of HVA VI and disclaims beneficial ownership of the shares held by Hatteras VI except to the extent of his pecuniary interest therein, if any.

F3: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.76 to $3.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 ConversionSeries C-1 Preferred Stock · Derivative 149,320 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 33

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners III, LP

Disclosed balance after: 0

Underlying: Common Stock · 149,320 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 ConversionSeries B Preferred Stock · Derivative 94,874 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 32

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Affiliates III, LP

Disclosed balance after: 0

Underlying: Common Stock · 94,874 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 ConversionSeries B Preferred Stock · Derivative 1,044,764 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 31

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners III, LP

Disclosed balance after: 0

Underlying: Common Stock · 1,044,764 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 ConversionSeries AA Preferred Stock · Derivative 13,609 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 30

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Affiliates III, LP

Disclosed balance after: 0

Underlying: Common Stock · 13,609 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 ConversionSeries AA Preferred Stock · Derivative 174,699 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 29

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners III, LP

Disclosed balance after: 0

Underlying: Common Stock · 174,699 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 ConversionSeries 1 Preferred Stock · Derivative 4,846 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 28

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Catalysta Ventures, LLC

Disclosed balance after: 0

Underlying: Common Stock · 4,846 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.nature: Catalysta Ventures, LLC ("Catalysta") is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 ConversionSeries 1 Preferred Stock · Derivative 3,862 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 27

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Affiliates III, LP

Disclosed balance after: 0

Underlying: Common Stock · 3,862 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 ConversionSeries 1 Preferred Stock · Derivative 42,530 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 26

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners III, LP

Disclosed balance after: 0

Underlying: Common Stock · 42,530 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 ConversionSeries 1 Preferred Stock · Derivative 52,690 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 25

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners I, LP

Disclosed balance after: 0

Underlying: Common Stock · 52,690 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.nature: Catalysta Ventures, LLC ("Catalysta") is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 SaleSeries C-1 Preferred Stock · Derivative 994 $5.00 $4,970.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 24

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Venture Capital Multiplier Fund

Disclosed balance after: 40,420

Underlying: Common Stock · 994 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 Exercise / conversionSeries C-1 Preferred Stock · Derivative 41,414 $0.12 $4,969.68
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 23

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Venture Capital Multiplier Fund

Disclosed balance after: 41,414

Underlying: Common Stock · 41,414 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 Exercise / conversionWarrants to Purchase Series C-1 Preferred Stock · Derivative 41,414 $0.00 Strike: $0.12 $0.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 22

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Venture Capital Multiplier Fund

Disclosed balance after: 0

Underlying: Series C-1 Preferred Stock · 41,414 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F5 · derivative.exercise_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F5 · derivative.expiration_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F1 · derivative.underlying: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 SaleSeries C-1 Preferred Stock · Derivative 104 $5.00 $520.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 21

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Affiliates III, LP

Disclosed balance after: 13,558

Underlying: Common Stock · 104 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 Exercise / conversionSeries C-1 Preferred Stock · Derivative 4,309 $0.12 $517.08
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 20

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Affiliates III, LP

Disclosed balance after: 13,662

Underlying: Common Stock · 4,309 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 Exercise / conversionWarrants to Purchase Series C-1 Preferred Stock · Derivative 4,309 $0.00 Strike: $0.12 $0.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 19

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Affiliates III, LP

Disclosed balance after: 0

Underlying: Series C-1 Preferred Stock · 4,309 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F5 · derivative.exercise_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F5 · derivative.expiration_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F1 · derivative.underlying: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 SaleSeries C-1 Preferred Stock · Derivative 1,139 $5.00 $5,695.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 18

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners III, LP

Disclosed balance after: 149,320

Underlying: Common Stock · 1,139 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 Exercise / conversionSeries C-1 Preferred Stock · Derivative 47,458 $0.12 $5,694.96
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 17

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners III, LP

Disclosed balance after: 150,459

Underlying: Common Stock · 47,458 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 Exercise / conversionWarrants to Purchase Series C-1 Preferred Stock · Derivative 47,458 $0.00 Strike: $0.12 $0.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 16

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners III, LP

Disclosed balance after: 0

Underlying: Series C-1 Preferred Stock · 47,458 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F5 · derivative.exercise_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F5 · derivative.expiration_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F1 · derivative.underlying: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 SaleSeries B Preferred Stock · Derivative 42 $5.00 $210.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 15

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Affiliates III, LP

Disclosed balance after: 94,874

Underlying: Common Stock · 42 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 Exercise / conversionSeries B Preferred Stock · Derivative 1,731 $0.12 $207.72
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 14

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Affiliates III, LP

Disclosed balance after: 94,916

Underlying: Common Stock · 1,731 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 Exercise / conversionWarrants to Purchase Series B Preferred Stock · Derivative 1,731 $0.00 Strike: $0.12 $0.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 13

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Affiliates III, LP

Disclosed balance after: 0

Underlying: Series B Preferred Stock · 1,731 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F5 · derivative.exercise_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F5 · derivative.expiration_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F1 · derivative.underlying: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 SaleSeries B Preferred Stock · Derivative 458 $5.00 $2,290.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 12

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners III, LP

Disclosed balance after: 1,044,764

Underlying: Common Stock · 458 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 Exercise / conversionSeries B Preferred Stock · Derivative 19,061 $0.12 $2,287.32
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 11

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners III, LP

Disclosed balance after: 1,045,222

Underlying: Common Stock · 19,061 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 Exercise / conversionWarrants to Purchase Series B Preferred Stock · Derivative 19,061 $0.00 Strike: $0.12 $0.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · derivative · entry 10

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners III, LP

Disclosed balance after: 0

Underlying: Series B Preferred Stock · 19,061 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F5 · derivative.exercise_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F5 · derivative.expiration_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F1 · derivative.underlying: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 PurchaseCommon Stock 150,000 $5.00 $750,000.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 9

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Venture Capital Multiplier Fund

Disclosed balance after: 416,481

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 ConversionCommon Stock 266,481 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 8

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Venture Capital Multiplier Fund

Disclosed balance after: 266,481

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 ConversionCommon Stock 4,846 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 7

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Catalysta Ventures, LLC

Disclosed balance after: 4,846

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.nature: Catalysta Ventures, LLC ("Catalysta") is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 PurchaseCommon Stock 12,487 $5.00 $62,435.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 6

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Affiliates III, LP

Disclosed balance after: 163,099

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 ConversionCommon Stock 150,612 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 5

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Affiliates III, LP

Disclosed balance after: 150,612

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 PurchaseCommon Stock 137,513 $5.00 $687,565.00
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 4

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners III, LP

Disclosed balance after: 1,820,933

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 ConversionCommon Stock 1,683,420 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 3

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners III, LP

Disclosed balance after: 1,683,420

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3 · ownership.nature: Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of his pecuniary interest therein.

Read SEC document
October 22, 2018 Filed Oct 24, 2018 16:19 UTC PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 ConversionCommon Stock 52,690 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-056051 · doc4.xml · nonDerivative · entry 2

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners I, LP

Disclosed balance after: 52,690

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.nature: Catalysta Ventures, LLC ("Catalysta") is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein.

Read SEC document
June 20, 2018 Filed Jun 21, 2018 21:23 UTC Clearside Biomedical, Inc. CLSD · Entity 82875 GrantStock Option (right to buy) · Derivative 11,250 $0.00 Strike: $10.74 $0.00
Disclosure

SEC source: 0001209191-18-038988 · doc4.xml · derivative · entry 1

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,250

Underlying: Common Stock · 11,250 shares

Expires 2028-06-19

F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2019.

Read SEC document
May 30, 2018 Filed Jun 1, 2018 18:22 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 SaleCommon Stock 41,710 $48.00 $2,002,080.00
Disclosure

SEC source: 0001209191-18-034839 · doc4.xml · nonDerivative · entry 2

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,237,711

F1 · ownership.nature: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F4 · ownership.nature: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC.

F5 · ownership.nature: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV.

Read SEC document
May 30, 2018 Filed Jun 1, 2018 18:22 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 SaleCommon Stock 758,290 $48.00 $36,397,920.00
Disclosure

SEC source: 0001209191-18-034839 · doc4.xml · nonDerivative · entry 1

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,279,421

F1 · ownership.nature: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F2 · ownership.nature: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F3 · ownership.nature: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

Read SEC document
May 23, 2018 Filed May 23, 2018 20:46 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 SaleCommon Stock 26 $50.50 $1,313.00
Disclosure

SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 8

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,037,711

F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F12 · ownership.nature: Following the reported transaction, 3,826,252 shares of the reportable securities are owned directly by HVP IV.

F13 · ownership.nature: Following the reported transaction, 210,464 shares of the reportable securities are owned directly by Hatteras NC.

Read SEC document
May 23, 2018 Filed May 23, 2018 20:46 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 SaleCommon Stock 474 $50.50 $23,937.00
Disclosure

SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 7

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,037,737

F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F11 · ownership.nature: Following the reported transaction, 210,490 shares of the reportable securities are owned directly by Hatteras NC.

F12 · ownership.nature: Following the reported transaction, 3,826,252 shares of the reportable securities are owned directly by HVP IV.

Read SEC document
May 22, 2018 Filed May 23, 2018 20:46 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 SaleCommon Stock 308 $50.69 $15,611.01
Disclosure

SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 6

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,038,211

F9 · price: The price represents the weighted average price with a low of $50.50 and a high of $51.25.

F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F10 · ownership.nature: Following the reported transaction, 3,826,726 shares of the reportable securities are owned directly by HVP IV.

F11 · ownership.nature: Following the reported transaction, 210,490 shares of the reportable securities are owned directly by Hatteras NC.

Read SEC document
May 22, 2018 Filed May 23, 2018 20:46 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 SaleCommon Stock 5,592 $50.86 $284,405.21
Disclosure

SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 5

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,038,519

F9 · price: The price represents the weighted average price with a low of $50.50 and a high of $51.25.

F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F8 · ownership.nature: Following the reported transaction, 210,798 shares of the reportable securities are owned directly by Hatteras NC.

F10 · ownership.nature: Following the reported transaction, 3,826,726 shares of the reportable securities are owned directly by HVP IV.

Read SEC document
May 21, 2018 Filed May 23, 2018 20:46 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 SaleCommon Stock 26 $52.13 $1,355.38
Disclosure

SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 4

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,044,111

F6 · price: The price represents the weighted average price with a low of $52.12 and a high of $52.14.

F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F7 · ownership.nature: Following the reported transaction, 3,832,318 shares of the reportable securities are owned directly by HVP IV.

F8 · ownership.nature: Following the reported transaction, 210,798 shares of the reportable securities are owned directly by Hatteras NC.

Read SEC document
May 21, 2018 Filed May 23, 2018 20:46 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 SaleCommon Stock 474 $52.13 $24,709.62
Disclosure

SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 3

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,044,137

F6 · price: The price represents the weighted average price with a low of $52.12 and a high of $52.14.

F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F5 · ownership.nature: Following the reported transaction, 210,824 shares of the reportable securities are owned directly by Hatteras NC.

F7 · ownership.nature: Following the reported transaction, 3,832,318 shares of the reportable securities are owned directly by HVP IV.

Read SEC document
May 21, 2018 Filed May 23, 2018 20:46 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 SaleCommon Stock 1,595 $51.06 $81,438.95
Disclosure

SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 2

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,044,611

F1 · price: The price represents the weighted average price with a low of $51.00 and a high of $51.755. The Reporting Persons undertake to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.

F2 · ownership.nature: Following the reported transaction, 3,832,792 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F5 · ownership.nature: Following the reported transaction, 210,824 shares of the reportable securities are owned directly by Hatteras NC.

Read SEC document
May 21, 2018 Filed May 23, 2018 20:46 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 SaleCommon Stock 29,005 $51.16 $1,483,907.40
Disclosure

SEC source: 0001209191-18-032789 · doc4.xml · nonDerivative · entry 1

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,046,206

F1 · price: The price represents the weighted average price with a low of $51.00 and a high of $51.755. The Reporting Persons undertake to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.

F2 · ownership.nature: Following the reported transaction, 3,832,792 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F3 · ownership.nature: Following the reported transaction, 212,419 shares of the reportable securities are owned directly by Hatteras NC Fund, LP ("Hatteras NC"). Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC Fund, LP. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member" and collectively, the "HVA IV Managing Members"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F4 · ownership.nature: 995 shares of the reportable securities are owned directly by Hatteras Venture Advisors V, LLC ("HVA V"). The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

Read SEC document
May 18, 2018 Filed May 21, 2018 20:05 UTC Clearside Biomedical, Inc. CLSD · Entity 82875 SaleCommon Stock 61,139 $13.16 $804,589.24
Disclosure

SEC source: 0001209191-18-031802 · doc4.xml · nonDerivative · entry 2

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,466,394

F5 · shares: Consists of (i) 1,737 shares sold by Hatteras NC, (ii) 23,497 shares sold by HVP III, (iii) 2,108 shares sold by HVA III, (iv) 3,791 shares sold by HVP IV and (v) 30,006 shares sold by HVP IV SBIC.

F6 · price: This transaction was executed in multiple trades at prices ranging from $12.97 to $13.41, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.

F4 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
May 17, 2018 Filed May 21, 2018 20:05 UTC Clearside Biomedical, Inc. CLSD · Entity 82875 SaleCommon Stock 100,000 $13.03 $1,303,000.00
Disclosure

SEC source: 0001209191-18-031802 · doc4.xml · nonDerivative · entry 1

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,527,533

F1 · shares: Consists of (i) 3,000 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 38,300 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 3,500 shares sold by Hatteras Venture Affiliates III, LP ("HVA III"), (iv) 6,200 shares sold by Hatteras Venture Partners IV, LP ("HVP IV") and (v) 49,000 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC").

F2 · price: This transaction was executed in multiple trades at prices ranging from $12.23 to $13.37, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.

F4 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
March 23, 2018 Filed Mar 23, 2018 21:51 UTC Clearside Biomedical, Inc. CLSD · Entity 82875 SaleCommon Stock 5,231 $12.02 $62,876.62
Disclosure

SEC source: 0001209191-18-021497 · doc4.xml · nonDerivative · entry 3

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,627,533

F7 · shares: Consists of (i) 154 shares sold by Hatteras NC, (ii) 2,006 shares sold by HVP III, (iii) 182 shares sold by HVA III, (iv) 324 shares sold by HVP IV and (v) 2,565 shares sold by HVP IV SBIC.

F8 · price: This transaction was executed in multiple trades at prices ranging from $12.00 to $12.10, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.

F4 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
March 22, 2018 Filed Mar 23, 2018 21:51 UTC Clearside Biomedical, Inc. CLSD · Entity 82875 SaleCommon Stock 33,630 $12.07 $405,914.10
Disclosure

SEC source: 0001209191-18-021497 · doc4.xml · nonDerivative · entry 2

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,632,764

F5 · shares: Consists of (i) 989 shares sold by Hatteras NC, (ii) 12,897 shares sold by HVP III, (iii) 1,170 shares sold by HVA III, (iv) 2,085 shares sold by HVP IV and (v) 16,489 shares sold by HVP IV SBIC.

F6 · price: This transaction was executed in multiple trades at prices ranging from $12.00 to $12.21, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.

F4 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
March 21, 2018 Filed Mar 23, 2018 21:51 UTC Clearside Biomedical, Inc. CLSD · Entity 82875 SaleCommon Stock 100,000 $12.27 $1,227,000.00
Disclosure

SEC source: 0001209191-18-021497 · doc4.xml · nonDerivative · entry 1

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,666,394

F1 · shares: Consists of (i) 2,940 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 38,350 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 3,480 shares sold by Hatteras Venture Affiliates III, LP ("HVA III"), (iv) 6,200 shares sold by Hatteras Venture Partners IV, LP ("HVP IV") and (v) 49,030 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC").

F2 · price: This transaction was executed in multiple trades at prices ranging from $12.00 to $12.49, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.

F4 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
December 07, 2017 Filed Dec 7, 2017 22:10 UTC Clearside Biomedical, Inc. CLSD · Entity 82875 SaleCommon Stock 5,000 $6.13 $30,650.00
Disclosure

SEC source: 0001209191-17-064491 · doc4.xml · nonDerivative · entry 3

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,766,394

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on June 12, 2017.

F8 · shares: Consists of (i) 4,584 shares sold by HVP III and (ii) 416 shares sold by HVA III.

F9 · price: This transaction was executed in multiple trades at prices ranging from $5.85 to $6.35, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F4 · ownership.nature: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of Hatteras Venture Partners IV SBIC, LP; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP. HVP III, HVA III, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP.

F5 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
December 06, 2017 Filed Dec 7, 2017 22:10 UTC Clearside Biomedical, Inc. CLSD · Entity 82875 SaleCommon Stock 15,000 $6.09 $91,350.00
Disclosure

SEC source: 0001209191-17-064491 · doc4.xml · nonDerivative · entry 2

Thorp Clay · CIK 0001592380 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,771,394

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on June 12, 2017.

F6 · shares: Consists of (i) 13,751 shares sold by HVP III and (ii) 1,249 shares sold by HVA III.

F7 · price: This transaction was executed in multiple trades at prices ranging from $5.93 to $6.26, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F4 · ownership.nature: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of Hatteras Venture Partners IV SBIC, LP; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP. HVP III, HVA III, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP.

F5 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.